We are live on
!
Find out more
AQR Capital Management Portfolio holdings
AUM
$218B
1-Year Est. Return
29.41%
This Fund
S&P 500
This Quarter
Est. Return
+10.92%
1 Year Est. Return
+29.41%
3 Year Est. Return
+92.15%
5 Year Est. Return
+116.61%
10 Year Est. Return
+435.72%
AUM
$43.9B
AUM Growth
+$2.87B
(+7%)
Cap. Flow
-$890M
Cap. Flow
% of AUM
-2.03%
Top 10 Holdings %
Top 10 Hldgs %
13.25%
Holding
2,343
New
170
Increased
997
Reduced
1,015
Closed
150
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Humana
HUM
|
+$111M |
| 2 |
Verizon
VZ
|
+$103M |
| 3 |
AT&T
T
|
+$103M |
| 4 |
Kroger
KR
|
+$97.1M |
| 5 |
3M
MMM
|
+$92.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$138M |
| 2 |
Tesla
TSLA
|
+$110M |
| 3 |
JPMorgan Chase
JPM
|
+$103M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$89.4M |
| 5 |
Apple
AAPL
|
+$85.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Healthcare | 16.25% |
| 3 | Financials | 11.85% |
| 4 | Industrials | 11.44% |
| 5 | Consumer Discretionary | 10.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2026
Seagate
STX
$182B
| $250K | ﹤0.01% |
4,762
-56,301
| -92% | -$2.99M |
|
2027
Enterprise Financial Services Corp
EFSC
$2.38B
| $250K | ﹤0.01% |
+5,101
| New | +$253K |
|
2028
Pennant Group
PNTG
$1.38B
| $246K | ﹤0.01% |
+22,386
| New | +$243K |
|
2029
Frontier Group Holdings
ULCC
$1.56B
| $244K | ﹤0.01% |
+23,754
| New | +$276K |
|
2030
BayCom
BCML
$332M
| $241K | ﹤0.01% |
12,708
-15,399
| -55% | -$290K |
|
2031
Arrowhead Research
ARWR
$12.5B
| $241K | ﹤0.01% |
6,024
-16,928
| -74% | -$561K |
|
2032
Interactive Brokers
IBKR
$41.1B
| $240K | ﹤0.01% |
+13,248
| New | +$247K |
|
2033
Esquire Financial Holdings
ESQ
$1.12B
| $239K | ﹤0.01% |
5,532
+204
| +4% | +$8.65K |
|
2034
CoreCivic
CXW
$3.26B
| $239K | ﹤0.01% |
20,652
+6,893
| +50% | +$76.5K |
|
2035
Artisan Partners
APAM
$3B
| $238K | ﹤0.01% |
8,013
-5,339
| -40% | -$164K |
|
2036
KBR
KBR
$4.83B
| $238K | ﹤0.01% |
4,570
-420
| -8% | -$20.9K |
|
2037
SSR Mining
SSRM
$6.4B
| $237K | ﹤0.01% |
+15,137
| New | +$222K |
|
2038
Liquidia Corp
LQDA
$8.1B
| $236K | ﹤0.01% |
37,041
-4,414
| -11% | -$23.7K |
|
2039
Anavex Life Sciences
AVXL
$314M
| $235K | ﹤0.01% |
25,378
-393
| -2% | -$4.2K |
|
2040
Farmers & Merchants Bancorp
FMAO
$473M
| $235K | ﹤0.01% |
8,628
+201
| +2% | +$5.66K |
|
2041
Uranium Energy
UEC
$5.63B
| $234K | ﹤0.01% |
60,369
+224
| +0.4% | +$850 |
|
2042
Brady Corp
BRC
$4.54B
| $234K | ﹤0.01% |
+4,960
| New | +$227K |
|
2043
Dimensional US Core Equity 2 ETF
DFAC
$49.5B
| $231K | ﹤0.01% |
+9,513
| New | +$231K |
|
2044
UFP Technologies
UFPT
$2.52B
| $231K | ﹤0.01% |
+1,957
| New | +$209K |
|
2045
Frontline
FRO
$8.56B
| $229K | ﹤0.01% |
18,892
-8,621
| -31% | -$111K |
|
2046
Cogent Communications
CCOI
$528M
| $229K | ﹤0.01% |
+4,015
| New | +$220K |
|
|
BKI
2047
DELISTED
Black Knight, Inc. Common Stock
BKI
| $228K | ﹤0.01% |
3,739
+239
| +7% | +$14.5K |
|
2048
The GEO Group
GEO
$4.04B
| $227K | ﹤0.01% |
20,736
+7,003
| +51% | +$68.1K |
|
2049
Collegium Pharmaceutical
COLL
$882M
| $227K | ﹤0.01% |
+9,773
| New | +$197K |
|
2050
HealthEquity
HQY
$8.93B
| $226K | ﹤0.01% |
+3,710
| New | +$249K |
|
Similar funds
VGA
AQR Capital Management's Q4 2022 Portfolio in Review
As of Q4 2022, AQR Capital Management held 2,343 positions worth $43.9B, up 7% from $41B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
AQR Capital Management's Q4 2022 filing shows 170 new, 997 increased, 1,015 reduced and 150 closed positions. Its largest new stake was Generac Holdings: 310,080 shares worth $30.5M. The largest sale was Gilead Sciences, an estimated $138M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Healthcare and Financials.
- AQR Capital Management's largest Q4 2022 buy was Generac Holdings: 310,080 shares worth $30.5M.
- AQR Capital Management added most to Humana in Q4 2022, an estimated $111M increase.
- AQR Capital Management's biggest Q4 2022 reduction was Gilead Sciences, cutting an estimated $138M.
- AQR Capital Management fully exited Abiomed Inc in Q4 2022, selling an estimated $22.4M.
- AQR Capital Management's ten largest holdings make up 13% of its $43.9B portfolio in Q4 2022.
- AQR Capital Management opened 170 new positions and closed 150 in Q4 2022.
- AQR Capital Management's portfolio value rose 7% quarter-over-quarter to $43.9B.
Based on AQR Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.